Focused On-demand Library for Leukemia inhibitory factor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P15018

UPID:

LIF_HUMAN

Alternative names:

Differentiation-stimulating factor; Melanoma-derived LPL inhibitor

Alternative UPACC:

P15018; B2RCW7; B5MC23; Q52LZ2

Background:

Leukemia inhibitory factor (LIF), also known as Differentiation-stimulating factor and Melanoma-derived LPL inhibitor, plays a pivotal role in cell differentiation, hematopoiesis, and inflammation. Its unique ability to induce terminal differentiation in leukemic cells, alongside promoting hematopoietic differentiation in both normal and myeloid leukemia cells, positions LIF as a critical player in cellular biology. Furthermore, LIF's involvement in neuronal cell differentiation and acute-phase protein synthesis in hepatocytes underscores its multifunctional nature.

Therapeutic significance:

Understanding the role of Leukemia inhibitory factor could open doors to potential therapeutic strategies. Its capacity to influence cell differentiation and immune responses highlights its potential as a target for developing treatments for leukemia and other conditions where cell differentiation and immune regulation are compromised.